BofA analyst Allen Lutz downgraded Omnicell (OMCL) to Neutral from Buy with a price target of $57, up from $44. The market is pricing in a clear return to growth for Omnicell’s Product business with shares up 30%, notes the analyst. However, while product extensions like XTAmplify can help drive incremental sales, visibility into growth is low, the analyst tells investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL: